COMMUNIQUÉS West-GlobeNewswire

Targovax ASA: Approval and publication of prospectus; the subsequent offering
30/06/2017
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE [...]
Targovax ASA: Extraordinary general meeting held, approval of private placement and subsequent offering
30/06/2017
NOT FOR DISTRIBUTION OR RELEASE, DIRECTLY OR INDIRECTLY IN OR INTO THE UNITED STATES, CANADA, JAPAN OR AUSTRALIA OR ANY OTHER JURISDICTION IN WHICH THE DISTRIBUTION OR RELEASE WOULD BE UNLAWFUL. OTHER RESTRICTIONS ARE [...]
Integrums bokslutskommuniké 1 maj 2016 - 30 april 2017
30/06/2017
PRESSINFORMATION 30 juni 2017 Integrum AB (publ) ("Integrum" eller "Bolaget") redovisade en nettoomsättning på 17 811 (12 324) KSEK under perioden 2016-05-01 till 2017-04-30 (12 månader), en ökning med 45 % jämfört med [...]
VALNEVA annonce le succès de son Assemblée Générale et la nomination de deux nouveaux membres à son Conseil de Surveillance
30/06/2017
Valneva annonce le succès de son Assemblée Générale et la nomination de deux nouveaux membres à son Conseil de Surveillance; Le Groupe confirme sa stratégie de croissance et ses perspectives R&D Lyon (France), 30 [...]
VALNEVA Announces Successful Outcome of its AGM and the Appointment of two new Supervisory Board Members
30/06/2017
Valneva Announces Successful Outcome of its AGM and the Appointment of two new Supervisory Board Members; The Company Confirms its Growth Strategy and R&D Outlook Lyon (France), June 30, 2017 - Valneva SE ("Valneva [...]
Befreiung von Publizitätspflichten zur Aufrechterhaltung der Kotierung
30/06/2017
ALLSCHWIL/BASEL, SCHWEIZ - 30. Juni 2017 - Am 16. Februar 2017 hat Janssen Holding GmbH, eine Tochtergesellschaft von Johnson & Johnson (NYSE:JNJ), den Angebotsprospekt zum öffentlichen Kaufangebot für alle sich im [...]
Résultats de l'Assemblée Générale Mixte d'AB Science du 28 juin 2017
29/06/2017
Paris, 29 juin 2017 Résultats de l'Assemblée Générale Mixte du 28 juin 2017 Les actionnaires de la société AB Science se sont réunis en Assemblée Générale Mixte, le mercredi 28 juin 2017, à 16 heures 00 au cabinet d' [...]
Aino Health AB (publ): Aino Health co-founds the corporate healthcare company Maresan Oy
29/06/2017
Aino Health AB (publ) subsidiary in Finland is the co-founder of corporate healthcare company Maresan Oy, together with several large shipping business partners. The main purpose of the new company will be to work [...]
Comprehensive Study by AstraZeneca and Genentech Confirms Superiority of InSphero Human Liver Microtissues for Prediction of Drug-Induced Liver Injury
29/06/2017
Archives of Toxicology publication reveals microtissues are twice as sensitive as 2D primary human hepatocytes (PHH) for predicting hepatotoxicity of 110 clinically defined DILI compounds. Schlieren, Switzerland, June [...]
iTeos Therapeutics SA: Appoints Mohamed Ragab, M.D. as Vice President, Corporate Development
29/06/2017
iTeos Therapeutics Appoints Mohamed Ragab, M.D. as Vice President, Corporate Development Joins from Bristol Myers Squibb to accelerate global partnering Gosselies, Belgium - June 29, 2017 - iTeos Therapeutics SA, a [...]
ObsEva Announces Presentations Related to its Assisted Reproductive Technology (ART) and Pre-term labor (PTL) Development Programs at ESHRE 2017 Annual Meeting
29/06/2017
Phase 2 nolasiban previously reported data supports potential for meaningfully increasing live birth rates in ART Non-clinical results of OBE022 for PTL demonstrate both monotherapy/combination potential Geneva, [...]
TiGenix opens US headquarters in Cambridge, MA
29/06/2017
PRESS RELEASE TiGenix opens US headquarters in Cambridge, MA Decision follows NASDAQ IPO in 2016 and the launch of the global phase III trial for Cx601 Operations to be based in Cambridge at heart of Boston area biotech [...]
TiGenix ouvre à Cambridge (Massachusetts) son siège central aux États-Unis
29/06/2017
COMMUNIQUÉ DE PRESSE TiGenix ouvre à Cambridge (Massachusetts) son siège central aux États-Unis La décision suit l'OPV de NASDAQ en 2016 et le lancement de l'essai clinique global de phase III pour Cx601 Les opérations [...]
Bio-on presents "The Matter". Bioplastic technology now open source for researchers around the world
29/06/2017
Bio-on presents "The Matter". Bioplastic technology now open source for researchers around the world Bio-on will make its natural and 100% biodegradable bioplastic, Minerv PHAs, available free of charge to researchers, [...]
Bio-on présente «The Matter». La technologie du bioplastique est désormais « Open source » au service des chercheurs du monde entier.
29/06/2017
Bio-on présente « The Matter ». La technologie du bioplastique est désormais « Open source » au service des chercheurs du monde entier. Bio-on mettra gratuitement le bioplastique naturel et entièrement (100%) [...]
Novartis receives EU approval for first-line use of Zykadia® in ALK-positive advanced non-small cell lung cancer (NSCLC)
29/06/2017
In ALK-positive advanced NSCLC patients, Zykadia demonstrated superior median progression-free survival (PFS) compared to SOC chemotherapy with maintenance[1] Zykadia benefit was also seen in patients with brain [...]
Minerva Neurosciences Announces Pricing of Public Offering of Common Stock
29/06/2017
WALTHAM, Mass., June 28, 2017 (GLOBE NEWSWIRE) -- Minerva Neurosciences, Inc. (NASDAQ:NERV), a clinical-stage biopharmaceutical company, today announced the pricing of an underwritten public offering of 5,000,000 shares [...]
Vectura Group plc: New development and licence agreement for a US inhaled generic (VR2081)
28/06/2017
Vectura Group plc New development and licence agreement for a US inhaled generic (VR2081) Chippenham, UK - 28 June 2017: Vectura Group plc (LSE: VEC) ("Vectura", "the Group"), an industry-leading device and formulation [...]
Innocoll Announces Scheme Meeting and Extraordinary General Meeting Voting Results
28/06/2017
NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION, IN WHOLE OR IN PART, IN, INTO OR FROM ANY JURISDICTION WHERE TO DO SO WOULD CONSTITUTE A VIOLATION OF THE RELEVANT LAWS OR REGULATIONS OF THAT JURISDICTION FOR IMMEDIATE [...]

Pages